Author:
Fukasawa Toshiki,Nakanishi Etsuro,Shimoda Hiroo,Shinoda Katsumi,Ito Satoru,Asada Shinji,Yoshida Satomi,Tanaka-Mizuno Sachiko,Mizuno Kayoko,Takahashi Ryosuke,Kawakami Koji
Funder
Kyowa Kirin Pharmaceutical Development
Kyowa Kirin Co Ltd
Reference56 articles.
1. Istradefylline: first global approval;Dungo;Drugs,2013
2. The belated US FDA approval of the adenosine A2A receptor antagonist istradefylline for treatment of Parkinson’s disease;Chen;Purinergic Signal,2020
3. Efficacy of istradefylline for gait disorders with freezing of gait in Parkinson’s disease: a single-arm, open-label, prospective, multicenter study;Iijima;Expert. Opin. Pharmacother.,2019
4. Efficacy and safety of istradefylline in patients with Parkinson’s disease presenting with postural abnormalities: results from a multicenter, prospective, and open-label exploratory study in Japan;Takahashi;J. Neurol. Sci.,2022
5. Effect of istradefylline on mood disorders in Parkinson’s disease;Nagayama;J. Neurol. Sci.,2019